Home  /  Resource Library  /  Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Results of a phase I/II study investigating the combination of Brentuximab Vedotin, Nivolumab and Ipilimumab for treatment of relapsed Hodgkin lymphoma.